BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28384560)

  • 1. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus.
    Lunder M; Janić M; Savić V; Janež A; Kanc K; Šabovič M
    Diabetes Res Clin Pract; 2017 May; 127():181-186. PubMed ID: 28384560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males.
    Janić M; Lunder M; Prezelj M; Šabovič M
    J Cardiopulm Rehabil Prev; 2014; 34(3):208-12. PubMed ID: 24263076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
    Boncelj Svetek M; Eržen B; Kanc K; Šabovič M
    J Diabetes Complications; 2017 Mar; 31(3):544-550. PubMed ID: 28012835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Fluvastatin and Valsartan Rejuvenate the Arterial Wall Through Telomerase Activity Increase in Middle-Aged Men.
    Janić M; Lunder M; Cerkovnik P; Prosenc Zmrzljak U; Novaković S; Šabovič M
    Rejuvenation Res; 2016 Apr; 19(2):115-9. PubMed ID: 26214555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.
    Savić V; Eržen B; Janić M; Lunder M; Boncelj M; Kanc K; Janež A; Šabović M
    Diab Vasc Dis Res; 2013 Sep; 10(5):420-5. PubMed ID: 23811602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease].
    Soboleva GN; Pogorelova OA; Kuznetsova TV; Masenko VP; Fomicheva OA; Chernova NA; Rogoza AN; Balakhonova TV; Karpov IuA
    Kardiologiia; 2007; 47(11):9-13. PubMed ID: 18260957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study.
    Turk Veselič M; Žorž N; Eržen B; Škerl P; Novaković S; Janić M; Šabovič M
    Int Angiol; 2018 Oct; 37(5):356-364. PubMed ID: 29952159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels.
    Schneider MP; Schmidt BM; John S; Schmieder RE
    J Hypertens; 2011 Sep; 29(9):1757-64. PubMed ID: 21799442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
    Lunder M; Janić M; Jug B; Sabovič M
    Eur J Intern Med; 2012 Apr; 23(3):261-6. PubMed ID: 22385885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
    Janić M; Lunder M; France Štiglic A; Jerin A; Skitek M; Černe D; Marc J; Drevenšek G; Šabovič M
    Vascul Pharmacol; 2017 Dec; 99():45-52. PubMed ID: 28951255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
    Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
    Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
    Hussein O; Shneider J; Rosenblat M; Aviram M
    J Cardiovasc Pharmacol; 2002 Jul; 40(1):28-34. PubMed ID: 12072574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
    Trials; 2015 Aug; 16():336. PubMed ID: 26248619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.
    Ruiz-Limon P; Barbarroja N; Perez-Sanchez C; Aguirre MA; Bertolaccini ML; Khamashta MA; Rodriguez-Ariza A; Almadén Y; Segui P; Khraiwesh H; Gonzalez-Reyes JA; Villalba JM; Collantes-Estevez E; Cuadrado MJ; Lopez-Pedrera C
    Ann Rheum Dis; 2015 Jul; 74(7):1450-8. PubMed ID: 24658835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia.
    Leu HB; Wu CC; Wu TC; Lin SJ; Chen JW
    J Formos Med Assoc; 2004 Dec; 103(12):914-20. PubMed ID: 15624040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin Decreases Oxidative Stress in Kidney Transplant Patients.
    Yildiz A; Gul CB; Ocak N; Ersoy A; Sag S; Oruc A; Ayar Y; Dagel T; Dirican M; Gullulu M
    Transplant Proc; 2015 Dec; 47(10):2870-4. PubMed ID: 26707305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
    Li Z; Iwai M; Wu L; Liu HW; Chen R; Jinno T; Suzuki J; Tsuda M; Gao XY; Okumura M; Cui TX; Horiuchi M
    Hypertension; 2004 Nov; 44(5):758-63. PubMed ID: 15452025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.